Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn's Disease.

Lee, Yoo Min; Kim, Eun Sil; Choi, Sujin; Jang, Hyo-Jeong; Kim, Yu Bin; Choi, So Yoon; Choe, Byung-Ho; Kang, Ben

Lee, Yoo Min; Kim, Eun Sil; Choi, Sujin; Jang, Hyo-Jeong; Kim, Yu Bin; Choi, So Yoon; Choe, Byung-Ho; Kang, Ben.

Afiliação

Lee YM; Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
Kim ES; Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi S; Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea.
Jang HJ; Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD), Daegu, Korea.
Kim YB; Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD), Daegu, Korea.
Choi SY; Department of Pediatrics, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea.
Choe BH; Department of Pediatrics, Ajou University Medical Center, Suwon, Korea.
Kang B; Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.

Gut Liver ; 2023 Nov 28.

Article em En | MEDLINE | ID: mdl-38013474

Palavras-chave

Calprotectin; Crohn disease; Infliximab; Prognosis

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Gut Liver Ano de publicação: 2023 Tipo de documento: Article